Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Accured Expenses (2020 - 2025)

Bioventus' Change in Accured Expenses history spans 6 years, with the latest figure at -$4.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 126.74% year-over-year to -$4.4 million; the TTM value through Dec 2025 reached -$19.8 million, down 211.03%, while the annual FY2025 figure was -$19.8 million, 211.03% down from the prior year.
  • Change in Accured Expenses reached -$4.4 million in Q4 2025 per BVS's latest filing, down from $7.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $29.9 million in Q2 2024 to a low of -$39.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $393450.0, with a median of $5.1 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 862.23% in 2021, then tumbled 911.94% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $11.0 million in 2021, then skyrocketed by 30.53% to $14.3 million in 2022, then plummeted by 59.53% to $5.8 million in 2023, then soared by 186.98% to $16.6 million in 2024, then tumbled by 126.74% to -$4.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Change in Accured Expenses are -$4.4 million (Q4 2025), $7.3 million (Q3 2025), and $16.4 million (Q2 2025).